Vitamin D deficiency in patients with Hodgkin’s disease may be a tell-tale sign of what is forbidding to come: poor progression-free survival (PFS) and overall survival (OS), according to an analysis of three studies.
The addition of the BTK* inhibitor ibrutinib to the monoclonal antibody rituximab resulted in improvement in progression-free survival (PFS) in treatment-naïve and relapsed patients with Waldenström’s macroglobulinaemia (WM) compared with placebo, according to results from the iNNOVATE (PCYC-1127)** trial presented at EHA 2018.
The second-generation chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (CTL019) continues to drive durable responses in pretreated patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to updated results from the JULIET* trial presented at EHA 2018.
A novel, immunomodulatory, chemotherapy-free combination comprising rituximab and lenalidomide (R2) demonstrated similar efficacy with the standard rituximab plus chemotherapy (R-chemo) followed by rituximab maintenance for advanced follicular lymphoma (FL), according to data from the RELEVANCE* trial presented at EHA 2018.
The selective FLT3* inhibitor quizartinib significantly improves survival compared with salvage chemotherapy in patients with relapsed/refractory acute myeloid leukaemia (AML) and FLT3-internal tandem duplication (ITD), regardless of prior haematopoietic stem cell transplantation (HSCT), reveals the QuANTUM-R** study presented at EHA 2018.
The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) led to improved progression-free survival (PFS) over VMP alone in elderly patients newly diagnosed with multiple myeloma (MM), reflecting the results of the overall ALCYONE* study population.
A combined regimen of obinutuzumab (a type II anti-CD20 antibody) and chlorambucil shows significant long-term survival benefit over rituximab plus chlorambucil or chlorambucil alone in patients with chronic lymphocytic leukaemia (CLL) and comorbidities who have not been treated previously, according to the final analysis of the CLL11* study presented at EHA 2018.
Adjusting treatment strategy based on results of a PET* scan performed after two cycles of escalated BEACOPP** potentially reduces exposure to toxicity and has comparable outcomes to a standard treatment regimen in patients with advanced Hodgkin lymphoma, according to the final analysis of the phase III AHL 2011 LYSA*** trial presented at EHA 2018.
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.